143 related articles for article (PubMed ID: 37276510)
1. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Fenaux P; Gobbi M; Kropf PL; Issa JJ; Roboz GJ; Mayer J; Krauter J; Robak T; Kantarjian H; Novak J; Jedrzejczak WW; Thomas X; Ojeda-Uribe M; Miyazaki Y; Min YH; Yeh SP; Brandwein J; Gercheva-Kyuchukova L; Demeter J; Griffiths E; Yee K; Döhner K; Hao Y; Keer H; Azab M; Döhner H
Blood Adv; 2023 Sep; 7(17):5027-5037. PubMed ID: 37276510
[TBL] [Abstract][Full Text] [Related]
2. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
3. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Roboz GJ; Sanz G; Griffiths EA; Yee K; Kantarjian H; Récher C; Byrne MT; Patkowska E; Kim HJ; Thomas X; Moors I; Stock W; Illés Á; Fenaux P; Miyazaki Y; Yamauchi T; O'Connell CL; Hao Y; Keer HN; Azab M; Döhner H
Blood Adv; 2024 Apr; 8(8):2020-2029. PubMed ID: 38231126
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Kantarjian HM; Thomas XG; Dmoszynska A; Wierzbowska A; Mazur G; Mayer J; Gau JP; Chou WC; Buckstein R; Cermak J; Kuo CY; Oriol A; Ravandi F; Faderl S; Delaunay J; Lysák D; Minden M; Arthur C
J Clin Oncol; 2012 Jul; 30(21):2670-7. PubMed ID: 22689805
[TBL] [Abstract][Full Text] [Related]
5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
6. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Garcia-Manero G; Roboz G; Walsh K; Kantarjian H; Ritchie E; Kropf P; O'Connell C; Tibes R; Lunin S; Rosenblat T; Yee K; Stock W; Griffiths E; Mace J; Podoltsev N; Berdeja J; Jabbour E; Issa JJ; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2019 Jun; 6(6):e317-e327. PubMed ID: 31060979
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Sébert M; Renneville A; Bally C; Peterlin P; Beyne-Rauzy O; Legros L; Gourin MP; Sanhes L; Wattel E; Gyan E; Park S; Stamatoullas A; Banos A; Laribi K; Jueliger S; Bevan L; Chermat F; Sapena R; Nibourel O; Chaffaut C; Chevret S; Preudhomme C; Adès L; Fenaux P;
Haematologica; 2019 Aug; 104(8):1565-1571. PubMed ID: 30733271
[TBL] [Abstract][Full Text] [Related]
9. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
[TBL] [Abstract][Full Text] [Related]
10. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
12. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Daher-Reyes GS; Merchan BM; Yee KWL
Expert Opin Investig Drugs; 2019 Oct; 28(10):835-849. PubMed ID: 31510809
[No Abstract] [Full Text] [Related]
13. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
[TBL] [Abstract][Full Text] [Related]
14. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
15. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Ravandi F; Roboz GJ; Wei AH; Döhner H; Pocock C; Selleslag D; Montesinos P; Sayar H; Musso M; Figuera-Alvarez A; Safah H; Tse W; Sohn SK; Hiwase D; Chevassut T; Pierdomenico F; La Torre I; Skikne B; Bailey R; Zhong J; Beach CL; Dombret H
J Hematol Oncol; 2021 Aug; 14(1):133. PubMed ID: 34454540
[TBL] [Abstract][Full Text] [Related]
16. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Ravandi F; Ritchie EK; Sayar H; Lancet JE; Craig MD; Vey N; Strickland SA; Schiller GJ; Jabbour E; Erba HP; Pigneux A; Horst HA; Recher C; Klimek VM; Cortes J; Roboz GJ; Odenike O; Thomas X; Havelange V; Maertens J; Derigs HG; Heuser M; Damon L; Powell BL; Gaidano G; Carella AM; Wei A; Hogge D; Craig AR; Fox JA; Ward R; Smith JA; Acton G; Mehta C; Stuart RK; Kantarjian HM
Lancet Oncol; 2015 Sep; 16(9):1025-1036. PubMed ID: 26234174
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
18. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Mayer J; Arthur C; Delaunay J; Mazur G; Thomas XG; Wierzbowska A; Ravandi F; Berrak E; Jones M; Li Y; Kantarjian HM
BMC Cancer; 2014 Feb; 14():69. PubMed ID: 24498872
[TBL] [Abstract][Full Text] [Related]
19. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
Roboz GJ; Kantarjian HM; Yee KWL; Kropf PL; O'Connell CL; Griffiths EA; Stock W; Daver NG; Jabbour E; Ritchie EK; Walsh KJ; Rizzieri D; Lunin SD; Curio T; Chung W; Hao Y; Lowder JN; Azab M; Issa JJ
Cancer; 2018 Jan; 124(2):325-334. PubMed ID: 29211308
[TBL] [Abstract][Full Text] [Related]
20. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
